The case for therapeutic proteostasis modulators

Neeraj Vij

Research output: Contribution to journalArticlepeer-review

Abstract

A functional ubiquitin proteasome pathway (UPP) is vital for all eukaryotic cellular systems and therefore any alteration in this critical component of proteostasis machinery has rpotential pathological consequences. A proteostasis imbalance can be induced by environmental pollutants, age or genetic factors. Though the exact underlying mechanisms are unclear, a decrease in proteasome activity weakens the homeostatic cellular capacity to remove proteins that are either misfolded or need to be replenished, which favors the development of neurodegenerative, cardiac and other conformational diseases. In contrast, induction of proteasome activity is an attribute of many diseases including muscle wasting, sepsis, cachexia and uraemia. In the case of misfolded protein disorders, higher degradation of a single protein leads to the pathophysiological consequences due to the absence of functional protein. Therefore, selective proteostasis inhibition is a potential treatment strategy for misfolded protein disorders, while broad-spectrum proteasome inhibitor drugs are designed to target tumor metastasis. In contrast, for muscle wasting and neurodegeneration, the use of proteostasis-activating or modulating compounds could be more effective.

Original languageEnglish (US)
Pages (from-to)233-236
Number of pages4
JournalExpert Opinion on Therapeutic Targets
Volume15
Issue number3
DOIs
StatePublished - Mar 2011

Keywords

  • Degradation
  • Proteasome
  • Proteostasis
  • Therapeutics
  • Ubiquitin

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint

Dive into the research topics of 'The case for therapeutic proteostasis modulators'. Together they form a unique fingerprint.

Cite this